Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Trial
Background/Objectives: Dendrimer-based astodrimer sodium nasal spray was assessed for its ability to reduce SARS-CoV-2 load in outpatients with COVID-19, which remains a severe illness for vulnerable groups. Methods: This was a randomised, double-blind, placebo-controlled clinical investigation eval...
Saved in:
Main Authors: | Stephen Winchester (Author), Alex Castellarnau (Author), Kashif Jabbar (Author), Meera Nadir (Author), Kapila Ranasinghe (Author), Xavier Masramon (Author), George R. Kinghorn (Author), Isaac John (Author), Jeremy R. A. Paull (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosis
by: Jane R. Schwebke, et al.
Published: (2021) -
Nasal saline as a placebo in a rhinosinusitis study
by: Karadag A, et al.
Published: (2014) -
Placebo
by: Mason, David, 1924-1974 -
Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold
by: Fazekas Tamas, et al.
Published: (2012) -
Three-weekly doses of azithromycin for Indigenous infants hospitalised with bronchiolitis: A multicentre, randomised, placebo-controlled trial
by: Gabrielle Britt McCallum, et al.
Published: (2015)